TABLE 1.

Presenting characteristics of the 6 SCO cases treated at our institutions

Case No.	Age (yrs), Sex	Presenting Sx	Primary, Recurrence, or Progression	Size (cm)	Tx	Intraop Events	Outcome/Subsequent Tx
1*	66, F	Dizziness, nausea, diaphoresis	Primary	1.7 × 2.1 × 2.4 (inf); 1.5 × 1.0 × 1.3 (sup)	TSR		Mild CN VI palsy resolved w/ dexameth; stable residual tumor (100 mos)
2*	50, M	Dizziness	Primary	1.2 × 1.4 × 1.3	TSR	Signif intraop venous bleeding	Stable residual tumor (30 mos)
3*	63, M	VD	Progression (3 mos postop from craniotomy at OSH)	2.7 × 2.7 × 1.9	TSR		Repeat TSR for tumor progression (3 mos postop); craniotomy for tumor progression (42 mos after repeat TSR)
4	59, F	HA, thyroid & adrenal hypopit, VD	Primary (transferred from an OSH due to intraop bleeding during craniotomy)		TSR	Excessive intraop bleeding	Recurrence 6 yrs after GTR, treated w/ repeat TSR, GKRS; stable (79 mos after initial presentation)
5	77, M	VD	Primary	2.4 × 2.8 × 2.2	TSR		Stable after GTR (12 mos)
6	56, F	Eyeball heaviness, nausea, dizziness	Progression (8.5 yrs after 2 TSRs, 1 craniotomy, CKRS at OSH)	3.8 × 4.2 × 4.1	TSR		Diplopia resolved 1 mo postop; proton beam therapy for residual tumor; stable residual tumor (38 mos after initial op at our institution)

CKRS = CyberKnife radiosurgery; CN = cranial nerve; dexameth = dexamethasone; GKRS = Gamma Knife radiosurgery; HA = headache; hypopit = hypopituitarism; inf = inferior; OSH = outside hospital; signif = significant; sup = superior; Sx = symptoms; TSR = transsphenoidal resection; Tx = treatment; VD = visual deficit.

^*These cases were previously reported with limited clinical detail in a study of SCO exome profiles.²³